CA
TVTX icon

Clearstead Advisors’s Travere Therapeutics TVTX Stock Holding History

Clearstead Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$399 Buy
+7
New +$310 ﹤0.01% 2994
2026
Q1 		– Sell
-9
Closed -$344 – 2816
2025
Q4 		$344 Sell
9
-91
-91% -$2.96K ﹤0.01% 2354
2025
Q3 		$2.39K Buy
+100
New +$1.88K ﹤0.01% 2401

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Clearstead Advisors's TVTX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 7 shares worth $399. The stake represents ﹤0.01% of the portfolio and ranks #2994 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in TVTX as recently as Q4 2025.

Clearstead Advisors first reported a position in TVTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.39K in Q3 2025. 110 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Clearstead Advisors held 7 shares of Travere Therapeutics worth $399 as of Q2 2026.
  • Travere Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2994 holding.
  • Clearstead Advisors first reported a position in Travere Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Clearstead Advisors's Travere Therapeutics position peaked at $2.39K in Q3 2025.
  • 110 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.